Amgen today is the biggest biotechnology company ... Its focus in those early days was on recombinant DNA technology, an exciting innovation that had only succeeded in producing its first ...

It has its own patent-protected DNA-encoded library drug discovery technology, which enables the efficient discovery of small molecule drug candidates, according to Amgen. The companies have been ...

Amgen's process patent describes the production of its erythropoietin product, Epogen, by expression of the cloned human EPO cDNA sequence, by placing the simian viral DNA promoter (SV40 ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ ... medical professionals choose treatments by keeping the DNA signature of an individual patient’s tumor in view.

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

CNBC's Angelica Peebles joins 'Closing Bell Overtime' with Amgen earnings ... discovered 50,000-year-old viruses in Neanderthal DNA that could help explain their mysterious extinction ...

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best drug stocks to buy now.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.